Glycemic Variability and the Risk of Diabetic Peripheral Neuropathy: A Meta-Analysis

Abstract

Glycemic variability (GV) has been related to complications in patients with diabetes. The aim of the systematic review and meta-analysis was to investigate whether GV is also associated with the incidence of diabetic peripheral neuropathy (DPN). A systematic search of Medline, Web of Science, Embase, and Cochrane Library database was conducted to identify relevant observational studies with longitudinal follow-up. The Newcastle-Ottawa Scale was used for study quality evaluation. A random-effects model was utilized to pool the results, accounting for heterogeneity. Ten observational studies including 72 565 patients with diabetes were included. The quality score was 8–9, indicating generally good quality of the included studies. With a mean follow-up duration of 7.1 years, 11 532 patients (15.9%) were diagnosed as DPN. Compared to patients with low GV, patients with high GV were associated with an increased risk incidence of DPN (risk ratio: 1.51, 95% confidence interval: 1.23 to 1.85, p<0.001; I2=78%). In addition, subgroup analysis showed consistent results in patients with type 1 and type 2 diabetes, and in studies evaluating the short-term and long-term GV (p for subgroup difference=0.82 and 0.53). Finally, results of subgroup analysis also suggested that the association between GV and risk of DPN were not significantly affected by study design, follow-up durations, diagnostic methods for DPN, adjustment of mean glycated hemoglobin A1c, or study quality scores (p for subgroup difference all>0.05). A high GV may be associated with an increased incidence of DPN.

Key words

glycemic variability - diabetic peripheral neuropathy - incidence - diabetes - meta-analysis

Publication History

Received: 24 July 2023

Accepted after revision: 28 August 2023

Article published online:
11 October 2023

• References

• 1 ElSayed NA, Aleppo G, Aroda VR. et al. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2023. Diabetes Care 2023; 46: S203-S215
• 2 Selvarajah D, Kar D, Khunti K. et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol 2019; 7: 938-948
• 3 Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol 2021; 17: 400-420
• 4 Alghamdi M, Owolabi LF, Adamu B. et al. Disease-specific quality of life in patients with diabetic neuropathy. Saudi Med J 2022; 43: 408-417
• 5 Elafros MA, Andersen H, Bennett DL. et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurol 2022; 21: 922-936
• 6 Faselis C, Katsimardou A, Imprialos K. et al. Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol 2020; 18: 117-124
• 7 Nusca A, Tuccinardi D, Albano M. et al. Glycemic variability in the development of cardiovascular complications in diabetes. Diabetes Metab Res Rev 2018; 34: e3047
• 8 Sun B, Luo Z, Zhou J. Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications. Cardiovasc Diabetol 2021; 20: 9
• 9 Ren X, Wang Z, Guo C. Long-term glycemic variability and risk of stroke in patients with diabetes: a meta-analysis. Diabetol Metab Syndr 2022; 14: 6
• 10 Belli M, Bellia A, Sergi D. et al. Glucose variability: a new risk factor for cardiovascular disease. Acta Diabetol 2023; 60: 1291-1299
• 11 Martinez M, Santamarina J, Pavesi A. et al. Glycemic variability and cardiovascular disease in patients with type 2 diabetes. BMJ Open Diabetes Res Care 2021; 9: e002032
• 12 Wang T, Zhang X, Liu J. Long-term glycemic variability and risk of cardiovascular events in type 2 diabetes: a meta-analysis. Horm Metab Res 2022; 54: 84-93
• 13 Umpierrez GE. P Kovatchev B Glycemic variability: how to measure and its clinical implication for type 2 diabetes. Am J Med Sci 2018; 356: 518-527
• 14 Zhou Z, Sun B, Huang S. et al. Glycemic variability: adverse clinical outcomes and how to improve it?. Cardiovasc Diabetol 2020; 19: 102
• 15 Zhang X, Yang X, Sun B. et al. Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review. Commun Biol 2021; 4: 1366
• 16 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
• 17 Page MJ, Moher D, Bossuyt PM. et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021; 372: n160
• 18 Higgins J, Thomas J, Chandler J. et al. Cochrane handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration. 2021 www.training.cochrane.org/handbook
• 19 Wells GA, Shea B, O’Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
• 20 Higgins J, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0. The Cochrane Collaboration. 2011 www.cochranehandbook.org
• 21 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
• 22 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
• 23 Bragd J, Adamson U, Backlund LB. et al. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?. Diabetes Metab 2008; 34: 612-616
• 24 Siegelaar SE, Kilpatrick ES, Rigby AS. et al. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 2009; 52: 2229-2232
• 25 Yang CP, Li CI, Liu CS. et al. Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM. Neurology 2017; 88: 944-951
• 26 Cardoso CRL, Leite NC, Moram CBM. et al. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol 2018; 17: 33
• 27 Pai YW, Lin CH, Lee IT. et al. Variability of fasting plasma glucose and the risk of painful diabetic peripheral neuropathy in patients with type 2 diabetes. Diabetes Metab 2018; 44: 129-134
• 28 Li S, Nemeth I, Donnelly L. et al. Visit-to-visit HbA(1c) variability is associated with cardiovascular disease and microvascular complications in patients with newly diagnosed type 2 diabetes. Diabetes Care 2020; 43: 426-432
• 29 Scott ES, Januszewski AS, O’Connell R. et al. Long-term glycemic variability and vascular complications in type 2 diabetes: post hoc analysis of the FIELD study. J Clin Endocrinol Metab 2020; 105: dgaa361
• 30 El Malahi A, Van Elsen M, Charleer S. et al. Relationship between time in range, glycemic variability, HbA1c, and complications in adults with type 1 diabetes mellitus. J Clin Endocrinol Metab 2022; 107: e570-e581
• 31 Mao Y, Zhong W. HbA1c Variability as an independent risk factor for microvascular complications in type 1 diabetes. J Diabetes Sci Technol. 2022 19322968221100833
• 32 Firouzabadi MD, Poopak A, Sheikhy A. et al. Glycemic profile variability: An independent risk factor for diabetic neuropathy in patients with type 2 diabetes. Prim Care Diabetes 2023; 17: 38-42
• 33 Qu F, Shi Q, Wang Y. et al. Visit-to-visit glycated hemoglobin A1c variability in adults with type 2 diabetes: a systematic review and meta-analysis. Chin Med J (Engl) 2022; 135: 2294-2300
• 34 Chen J, Yi Q, Wang Y. et al. Long-term glycemic variability and risk of adverse health outcomes in patients with diabetes: a systematic review and meta-analysis of cohort studies. Diabetes Res Clin Pract 2022; 192: 110085
• 35 Sartore G, Ragazzi E, Caprino R. et al. Long-term HbA1c variability and macro-/micro-vascular complications in type 2 diabetes mellitus: a meta-analysis update. Acta Diabetol 2023; 60: 721-738
• 36 Watt C, Sanchez-Rangel E, Hwang JJ. Glycemic variability and CNS inflammation: reviewing the connection. Nutrients 2020; 12: 3906
• 37 Papachristoforou E, Lambadiari V, Maratou E. et al. Association of glycemic indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications. J Diabetes Res 2020; 7489795
• 38 Huang Y, Yue L, Qiu J. et al. Endothelial dysfunction and platelet hyperactivation in diabetic complications induced by glycemic variability. Horm Metab Res 2022; 54: 419-428
• 39 Yang J, Zhao Z, Yuan H. et al. The mechanisms of glycemic variability accelerate diabetic central neuropathy and diabetic peripheral neuropathy in diabetic rats. Biochem Biophys Res Commun 2019; 510: 35-41
• 40 Clair C, Cohen MJ, Eichler F. et al. The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis. J Gen Intern Med 2015; 30: 1193-1203